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Abstract 
Objectives: Hypoxia is the condition where tumor cells have been deprived of oxygen and has been shown to have 
a role of tumor development in the hepatocellular carcinoma (HCC).
Methods: Using PubMed online database and Google scholar web site, the terms “angiogenesis”, “apoptosis”, “RNA 
interference” and/or “hepatocellular carcinoma (HCC)” were searched and analyzed.
Results: The hypoxia inducible factors (HIFs) are transcriptional regulators that affect a homeostatic response to 
oxidative stress and have been identified as a key transcription activator of angiogenesis, survival, and metabolism. 
Cytokines, such as IL-8, also controlled endothelia cells survival and angiogenesis. IL-8 was also overexpressed under 
hypoxia and induced tumor angiogenesis and growth.
Conclusion: Therefore, regulation of HIFs and IL-8 controlled the tumor microenvironment in terms of tumor angio-
genesis and apoptosis. The review summarizes the results of regulation of the hypoxic tumor environment.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer in the world [1]. HCC is the second most 
lethal cancer [1]. About 80–90% of cirrhotic liver disease 
due to chronic viral hepatitis B (HBV) or C (HCV) devel-
ops into HCC [1]. Moreover, most cases of advanced 
HCC develop hypoxic induction with angiogenesis and 
growth programs [2].
The most important factors that impact HCC progres-
sion are oxygen and nutrients [3]. The liver is an organ 
with a specific blood supply. Approximately 25 and 75% 
of the blood enters the liver through the hepatic artery 
and the portal vein, respectively. The latter drains into 
smaller-diameter structures called sinusoids. Vascu-
lar resistance is very low in these structures, and por-
tal venous blood, which is loaded with food and many 
microbial antigens from the intestine, flows extremely 
slowly into the sinusoids. Thus, large amounts of nutri-
ents and oxygen are required for HCC cell proliferation, 
which results in localized hypoxia [3, 4]. This hypoxia 
environment causes tumor angiogenesis, which is the 
generation of new blood vessels from already existing 
ones [3, 5]. Tumor angiogenesis overcomes oxidative 
stress and deficiency of oxygen-dependent energy pro-
duction caused by hypoxia [3]. The key factors responsi-
ble for the regulation of angiogenesis during hypoxia are 
HIF-1α and VEGF [5, 6]. However, various studies have 
reported that angiogenesis is induced even during inhi-
bition of HIF-1α during hypoxia [7], and these findings 
demonstrate that tumor angiogenesis is also partially 
recovered by various other factors [7]. The increase in 
expression of various factors such as growth factor and 
tumor stimulating factors during hypoxia can induce 
angiogenesis, as they increase proliferation and ensure 
stabilization of endothelial cells, which are not only 
caused by HIF-1α, but also by cytokines such as inter-
leukin IL-8, or other growth factors, such as PDGF [8, 9]. 
Open Access
Cancer Cell International
*Correspondence:  drpjy@yuhs.ac 
2 Department of Internal Medicine, Institute of Gastroenterology, Yonsei 
University College of Medicine, Seoul, Korea
Full list of author information is available at the end of the article
Page 2 of 8Choi and Park  Cancer Cell Int  (2017) 17:3 
They also increase VEGF expression as well as contribute 
to the increase and stabilization of angiogenesis by stim-
ulating of VEGFR on the surface of endothelial cells [10]. 
Moreover, various solid tumors pass through the follow-
ing three stages during their reproduction cycle: cell pro-
liferation, hypoxia, and recovery by angiogenesis [3].
Role of HIF and IL‑8 under hypoxia
The hypoxia inducible factors (HIFs) are a family of 
heterodimeric transcription factors that act as master 
regulators of a homeostatic transcriptional response to 
hypoxia in virtually all cells and tissues [3]. Active HIF 
consists of an alpha subunit and a beta subunit [2, 11, 12]. 
Three alpha subunits, termed HIF1a, HIF2a, and HIF3a, 
have been described in humans, mice, and rats; all bind 
to a common b subunit named, alternatively, HIF1b, or 
the aryl-hydrocarbon-nuclear receptor translocator 
(ARNT) [13, 14]. Active HIF is termed by its alpha subu-
nit; hence, HIF1 is the active transcription factor consist-
ing of HIF1α and ARNT, HIF2 is the dimer of HIF2α and 
ARNT, etc. [15]. HIF1 and HIF2 are the major hypoxia-
inducible factors in humans, mice, and rats [13].
Under conditions of normoxia, HIF-1α subunits are 
hydroxylated at proline residues by hydroxylase enzymes 
[3, 16]. Hydroxylation of HIF1α and assembly on a pro-
tein scaffold consisting of the VHL tumor suppressor 
[17–20], along with other cofactors, result in the rapid 
ubiquitination of the alpha subunit and subsequent deg-
radation by the proteasome. Conversely, in conditions of 
hypoxia, HIFα subunits escape degradation and are free 
to dimerize with the binding partner, ARNT [3, 13]. The 
HIF trans-locates to the nucleus and affects transcription 
of target genes, typically by binding to a hypoxia response 
element (HRE) in the upstream promoter region of the 
target genes such as, angiogenesis, apoptosis, metabo-
lism, survival related genes etc. [2, 3, 14].
Interlukine-8 (CXCL-8, IL-8) is a key factor of endothe-
lial cell survival and angiogenesis [21]. IL-8 is also regu-
lated under hypoxia and directly controlled endothelial 
cell [22–25]. IL-8 has been shown to regulate pathologi-
cal angiogenesis, tumor growth, and metastasis [24]. The 
mechanism(s) regulating IL-8-mediated endothelial cell 
survival are not well understood. Recent reports sug-
gest that in addition to cell proliferation and migration, 
endothelial cell survival and death are also important com-
ponents for tumor survival and development [25]. The 
other studies have shown that a cell cycle-regulated apop-
tosis inhibitor, survivin, and the cell death-related gene 
family products, Bcl-xl and Bcl-2 [15, 26], are associated 
with vascular endothelial growth factor (VEGF)-induced 
angiogenesis [10, 25]. IL-8 and its receptors CXCR1 and 
CXCR2 have been observed in endothelial cells and have 
been shown to play a role in endothelial cell proliferation 
[25]. Liver cancer, such as HCC, are dependent on angio-
genesis; therefore, angiogenesis inhibition can be used as 
a potential treatment modality to inhibit the proliferation 
and growth of solid tumors [27, 28]. In addition, efforts 
to treat solid tumors using angiogenesis inhibitors have 
yielded good results [28, 29]. However, these therapies not 
only affect solid tumors but also normal cells, which is an 
area of concern in cancer treatment [27]. Furthermore, 
cancer therapies, such as transarterial chemoemboliza-
tion (TACE) that uses blood vessels may not produce the 
desired results, and this may even increase vascular pro-
liferation and growth into a malignant tumor by incom-
plete responses [30]. A correlation between hypoxia, 
cancer proliferation, and angiogenesis and the mechanism 
of growth or development of tumors has been observed 
[31]. If the link between any of the above can be elucidated, 
the basis for inhibition of tumor growth and excision can 
be ascertained. This can be achieved by dual control of 
HIF-1α and angiogenic factors [6]. Innovative and more 
effective cancer therapies can be developed by regulating 
HIF-1α expression, which is the key factor in hypoxia, and 
controlling the expression of IL-8 and other angiogenic 
stimulators, which restore the angiogenic processes, dur-
ing inhibition of HIF-1α expression [7].
HIF-1α knockdown directly repressed tumor growth, 
whereas IL-8 knockdown indirectly repressed tumor 
growth [1, 7, 27]. Combined knockdown of HIF-1α and 
IL-8 increased survival rates of mice [7]. Conditioned 
media of Combined knockdown in HCC cells also 
decreased micro-vessel density and tumor volume in vivo 
[7]. Similarly, HIF-1α and IL-8 knockdown inhibited the 
angiogenic effects of HCC cell-conditioned media on 
tube formation and invasion by endothelial cells in vitro 
[7]. Inhibition of HIF-1α and IL-8 up-regulated the 
expression of apoptotic factors while down-regulating 
anti-apoptotic factors simultaneously [7]. Knockdown 
of HIF-1α and IL-8 increased concentration of cyto-
solic cytochrome C and enhanced DNA fragmentation 
in HCC cell lines and HUVECs [32]. Moreover, culture 
supernatant collected from the knockdown of HIF-1α 
and IL-8 in HCC cell lines induced apoptosis in HUVECs 
under hypoxia [32]. The silencing of HIF-1β expression 
suppressed tumor cell growth and inhibited the expres-
sion of tumor growth-related factors [33], such as vascu-
lar endothelial growth factor, epidermal growth factor, 
and hepatocyte growth factor. Suppression of tumor cell 
invasion and migration was also demonstrated in HIF-
1β-silenced HCC cell lines [33].
Inhibition of HIF‑1α and IL‑8 expression to suppress 
angiogenesis
Angiogenesis is essential for tumor growth and metas-
tasis, and attempts to control tumor-associated 
Page 3 of 8Choi and Park  Cancer Cell Int  (2017) 17:3 
angiogenesis may prove to be promising tactics for limit-
ing progression [27]. Angiogenesis occurs during devel-
opment and vascular remodeling as a controlled series 
of events leading to neovascularization, which supports 
changing tissue requirements [34]. Blood vessels and 
stromal components are responsive to pro- and anti-
angiogenic factors that allow vascular remodeling dur-
ing development, wound healing, and pregnancy [35, 
36]. However, in pathological situations, such as cancer, 
the same angiogenic signaling pathways are induced and 
exploited.
Although an oncogenic event may allow tumor cells to 
evade surveillance or may enhance their survival, large-
scale growth of a tumor ultimately requires a blood sup-
ply [27]. To obtain this blood supply, tumor cells can 
tilt the balance toward stimulatory angiogenic factors 
in order to drive vascular growth by attracting and acti-
vating cells from within the microenvironment of the 
tumor [37]. The magnitude and quality of the angiogenic 
response is ultimately determined by the sum of pro- and 
anti-angiogenic signals (Table  1) and, more specifically, 
their unique activities on multiple cell types [38]. Under-
standing how these various components are regulated is 
required for the design and development of effective anti-
angiogenic therapies for cancer [27].
In cancer, multiple sources and modes of vascular 
remodeling contribute to disease progression [28]. Tar-
geting one aspect of this remodeling process may pro-
duce a short-term effect; nevertheless, suppressing one 
pathway could promote another [7]. The redundancy 
and diversity by which blood vessels can remodel might 
account for the poor efficacy or acquired resistance 
often observed in antiangiogenic therapies [3]. Improv-
ing therapeutic responses thus requires consideration 
of the signaling pathways that regulate the multiple cell 
types involved in the vascular components of cancer [39]. 
Once a tumor lesion exceeds a few millimeters in diam-
eter, hypoxia and nutrient deprivation triggers an “angio-
genic switch” to allow the tumor to progress [3, 15, 27]. 
Tumor cells exploit their microenvironment by releasing 
cytokines and growth factors to activate normal, quies-
cent cells around them, initiating a cascade of events that 
quickly becomes dys-regulated [40].
Therefore, simultaneous inhibition of HIF-1α and IL-8 
expression has proven to be more effective in hindering 
angiogenesis than inhibition of a single factor [7, 32, 33]. 
With regards to expression at a molecular level, studies 
have demonstrated that liver cancer is regulated more 
by HIF-1α; however, in vascular endothelial cells, such 
as human umbilical vein endothelial cells (HUVEC), the 
level of IL-8 regulation is similar to that of HIF-1α [2, 
41, 42]. The growth of cancer cells and VEGF expres-
sion, which controls angiogenesis, has been observed 
to be regulated by HIF-1α, whereas IL-8 does not affect 
tumor growth or VEGF expression [7]. Alternatively, in 
HUVEC, when IL-8 expression is inhibited, angiogenic 
inhibition is observed at a level similar to HIF-1α inhibi-
tion (Fig. 1).
Similar results have been obtained through animal 
research; inhibition of HIF-1α expression rarely resulted 
in tumors reproduction in the animal models. Moreo-
ver, no apoptosis of existing tumors are observed in 
these animals; however, in other animal models, where 
IL-8 expression was inhibited, a tumor volume similar to 
the time when shIL-8 was injected into the tumors was 
observed. These findings did not reveal any correlation 
between IL-8 and direct growth of tumors; however, IL-8 
plays an important role in angiogenesis [24, 41, 43]. In 
addition, the results of the experiments on angiogenesis, 
such as invasion, tube formation, and aorta sprouting 
assays, have confirmed that simultaneous inhibition of 
two factors yielded more favorable responses than inhibi-
tion of a single factor [7]. Experiments with animal mod-
els have also demonstrated apoptosis of existing tumors 
as well as high survival rates in a majority of animals in 
which both the factors were inhibited. Moreover, it was 
confirmed that various factors to test for blood vessel for-
mation, such as CD31, CD34, and vascular endothelial 
Table 1 Up regulation of  tumor angiogenic factors 
under hypoxia
Factors Functions Ref
VEGF Increased vascular permeability [5]
Endothelial sprouting [36]
EC proliferation and migration [10, 35]
EC assembly [40]
iNO Increased vascular permeability [35]
Angiopoietin-2 Endothelial sprouting [36]
PDGF Pericyte recruting [9, 56]
EC proliferation and migration [3, 40]
MMPs Degradation of extracellular matrix [5]
Tie2 Form the blood vessels [40]
TGF-beta Increased EC differentiation formation of 
vascular structure
[35, 40]
Formed vascular structure [10, 40]
VEGFR2 Stimulate endothelial cell mitogenesis and cell 
migration
[3, 10]
Enhances microvascular permeability [5, 56]
Endothelin Regulates local vascular tone and integrity [10, 40]
Influences EC growth and survival [5]
IL-8 Increased vascular permeability [5]
EC proliferation and migration [25]
Endothelial sprouting [36]
Page 4 of 8Choi and Park  Cancer Cell Int  (2017) 17:3 
(V-E) cadherin, were not observed [7]. These findings 
suggested that controlling hypoxia as well as the expres-
sion of angiogenesis-associated factors that act via differ-
ent pathways can aid in the inhibition of angiogenesis.
Various treatments have been developed for cancer, 
and better therapies have been developed by overcom-
ing the limitations of already-developed treatments. 
We hypothesized that if the symptoms that occur dur-
ing tumor treatment can be studied and controlled, the 
obstacles currently encountered during cancer treatment 
can be eliminated. If simultaneous regulation of tumor 
development, hypoxia, and angiogenesis is possible, 
cancer cells could be easily treated without peripheral 
damage. In other words, simultaneous inhibition of the 
factors that potentially control hypoxia and angiogen-
esis during treatment to induce apoptosis may be a more 
innovative anticancer treatment modality.
Tumor escape from apoptosis under hypoxic conditions
A correlation exists between cancer and hypoxia [31]. 
Hypoxia during tumor development can destroy cancer 
cells; however, it acts as a key factor in excessive can-
cer proliferation [31, 44, 45]. Prevention of cancer via 
hypoxia treatment can be used as a highly effective anti-
cancer therapy [2, 34, 46]. To date, studies have been 
carried out to induce apoptosis in various tumors [2, 34, 
44, 47]. One potential treatment option involves reduc-
ing angiogenesis, typically by inhibiting VEGF, EGF, or 
bFGF, while an alternative option involves activating 
the intracellular intrinsic apoptosis pathway by induc-
ing the expression of apoptotic factors and inhibiting 
the expression of anti-apoptosis factors [31]. Moreover, 
a method to stimulate an extracellular death signal in 
order to induce apoptosis could also be developed. Apop-
tosis, also referred to as programmed cell death, is one 
of the most important cellular functions [48]. In nor-
mal cells, a decrease in telomere length normally occurs 
with age; however, DNA damage, toxin exposure, and 
deprivation of growth factor also generate death signals 
in various pathways, which results in apoptosis [49, 50]. 
Hypoxic stimulation is also a crucial death signal; apop-
tosis is induced when the oxygen supply, required for the 
production of ATP, an important cellular metabolite, is 
suppressed [31]. However, in tumors, stimulation that 
induces apoptosis can be avoided [51]. During telomere 
length decrease, production of telomerase is promoted to 
restore the length of telomeres, and when DNA damage 
is induced, it can be repaired by mutation [31, 34, 52]. In 
hypoxic conditions, apoptosis can be avoided by inducing 
angiogenesis while increasing the expression of growth 
factors, thereby restoring oxygen supply, or by stimulat-
ing intracellular nitric oxide synthase (iNOs) through 
hematopoiesis and local vasodilation (Table 2) [6, 11, 53]. 
Apoptosis can be also be avoided by increasing anaerobic 
ATP production via glycolysis, which is facilitated by pro-
moting GLUT1 or pyruvate dehydrogenase kinase activ-
ity [11].
HIF-1α, which is generated under hypoxic conditions, 
is an important anti-apoptotic factor [31, 45]. HIF-1, like 
tumor necrosis factor (TNF)-a, activates the expression 
of FoxM1, that in turn induces growth of cancer cells in 
the liver and increases resistance to apoptosis [50]. The 
expression of HIF-1 in liver cancer inhibits expression of 
various caspases and reduces expression of Bax and Bak, 
which lead to a higher concentration of cytochrome C 
inside the cells [32]. Increase in the expression of survivin 
Fig. 1 Inhibition of tumor angiogenesis by silencing of HIF-1α and IL-8. HIF-1α directly regulates HCC development and IL-8 assists tumor growth 
through regulation of angiogenesis in the vascular endothelial systems. shRNA-induced HIF-1α and IL-8 knockdown inhibit angiogenesis and tumor 
growth in HCC
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and the Bcl-family, which are important factors that 
cause DNA fragmentation, can prevent hypoxic apopto-
sis [54].
Apoptosis in tumors is important because tumor 
angiogenesis, which is increased by tumor prolifera-
tion, can also be inhibited [34]. Apoptosis in tumors can 
also induce apoptosis in newly formed peripheral blood 
vessels, thereby ensuring the prevention of a relapse of 
cancer or cancer stem cell growth at an early stage [1, 
27, 28]. The immunofluorescence-TUNEL technique 
has demonstrated that tumors in which HIF-1α expres-
sion is inhibited display increased DNA fragmenta-
tion [32]. Interestingly, although IL-8 does not exert 
a direct influence on tumor apoptosis, it plays a role in 
tumor apoptosis by controlling apoptosis in blood ves-
sels [32]. Cultivated tumor cell lines with simultaneous 
inhibition of these two factors demonstrated increase in 
tumor apoptosis via the FACS-TUNEL technique. It was 
also confirmed that a vascular endothelial cell culture 
medium developed from a culture medium, in which 
apoptosis had been induced in tumor cells, promoted 
apoptosis in vascular endothelial cells without any stimu-
lation (Fig. 2) [3, 32]. Apoptosis in tumors affects the sur-
rounding tissues owing to the constant communication 
and transmission between cells. The blood vessels, which 
are essential for tumor growth, mutually communicate 
via various factors that are present in the vicinity of the 
tumor. Therefore, cancer treatment and anticancer drugs 
can induce apoptosis in tumors while simultaneously reg-
ulating the expression of an activation factor in vascular 
endothelial cells, a higher anti-tumor therapeutic efficacy 
can be achieved during treatment of tumors [3, 32, 37]. In 
addition, a more precise tumor treatment can be devel-
oped by eliminating the factors that support the growth 
of malignant tumors, which relapse due to various rea-
sons after tumor treatment [27, 32].
Tumors can be treated using various methods and with 
several drugs [1]; the efficacy of these treatments can 
confirmed via different experiments. Moreover, various 
studies have been conducted to develop potential anti-
tumor treatments that work by regulating the micro-
environment of the tumor or controlling various tumor 
growth factors along with the existing tumor treatments 
[1, 22, 28, 39, 40]. Inhibition of the hypoxic mediator, 
HIF-1α, and the activation factor in V-E cells, IL-8, which 
is closely related to tumor development, can potentially 
be used to develop a treatment that can directly regulate 
tumor development as well as the microenvironment of 
tumors [7, 14, 20, 32].
Conclusion
Although newly developed treatments for HCC employ 
various approaches to combat the disease, all are associ-
ated with significant side effects and complications [1]. 
For example, in TACE, which uses vessel embolization to 
induce cancer tissue necrosis, surrounding tissue is also 
obliterated [30]. Furthermore, any remaining emboliza-
tion- or radiotherapy-resistant cancer tissue tends to be 
more malignant and can lead to metastasis [55, 56]. Addi-
tionally, hypoxia induced by medical or surgical treat-
ment induces the accumulation of HIF-1α inside tumor 
cells and its subsequent migration into the nuclei, where 
it promotes the expression of angiogenesis-related genes 
and increases oxygen supply to the tumor [57]. It also 
induces the expression of metastasis-related genes [12, 
17, 31]. These hypoxia-induced processes reduce cellular 
injury and enable continuous tumor growth by ensuring 
an effective supply of oxygen to the tumor [31].
In recent studies, the inhibition of HIF-1α expres-
sion failed to block angiogenesis induced by the tumor, 
allowing the tumor to survive and proliferate [7, 27]. 
The key factor involved in this process is IL-8, which is 
up-regulated by hypoxic conditions during tumor pro-
liferation [12, 56, 58]. IL-8 induces angiogenesis by acti-
vating vascular endothelial cells [59]. HIF-1α directly 
regulates HCC development and IL-8 assisted tumor 
growth through regulation of angiogenesis in the vas-
cular endothelial system [28] s. These findings might be 
used as a basis for the development of an effective treat-
ment that does not harm normal cells. However, further 
studies must be conducted before any clinical application. 
Although the inhibition of HIF-1α and IL-8 has been 
found to have a significant influence on tumor angiogen-
esis in animal studies, the effect thereof was restricted to 
specific hypoxic conditions. Since hypoxia destroys both 
tumor cells and normal cells, the expression of HIF-1α 
must be maintained in normal tissues.
Regarding tumor proliferation, a hypoxic state is 
important for tumor growth to start. It is thought that 
HIF-1 expression (HIF-1α and HIF-1β) controls the ini-
tiation of tumor growth and can affect anti-tumor growth 
by changing growth to be more malignant in a hypoxic 
Table 2 Role of anti-apoptosis under hypoxia
Factors Functions Ref
Bcl family Block BAX and BAD activity [11, 51]
Inhibited caspase activation [5, 44]
Inhibited cytochrome c release [31, 48]
BNIP Apoptotic protector [15]
TGF-alpha Induces epithelial development [26]
Initiate multiple cell proliferation [5, 44]
Caspase family Downreulgation of caspase-3 and 9 [31, 48]
JNK Regulates cell growth, differentiation, survival [18, 51]
up-regulated STAT3 [44]
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state. Further study is required to determine other pos-
sible functions of HIF-1β that are comparatively less 
known than those of HIF-1α, which has drawn most of 
the attention until now.
A local hypoxic microenvironment is one of the most 
important characteristics of solid tumors. Apoptosis is 
an important mechanism for the development of organ-
isms, which survive and proliferate in the cyclic struc-
ture of cell creation and death. However, apoptosis is 
also critical to inhibiting the growth of cancer cells. One 
of the significant survival mechanisms of cancer cells is 
the suppression or prevention of apoptosis. Once apop-
tosis is induced, cancer cells induce expression of various 
anti-apoptotic factors, thereby suppressing apoptosis. 
Thereby, the growth of cancer cells and tissues increases. 
Various anticancer agents or anticancer therapies have 
been rapidly developed to address this characteristic. 
TACE, which is currently widely utilized in the treat-
ment of liver cancer, induces hypoxia and hypoglycemia 
in liver cancer cells and reduces the numbers of cancer 
cells. Radiation therapies also induce an extended range 
of hypoxia in radiated areas, thereby promoting hypoxic 
apoptosis of the tissues. Among the various treatments of 
liver cancer, most methods induce apoptosis of the can-
cer cells, thereby killing them.
The present study investigated the effects of cancer-cell 
induction or prevention of apoptosis on peripheral vascu-
lar cells, rather than the direct treatment of cancer cells [34, 
40, 48]. Apoptosis of cancer cells was confirmed to influ-
ence the apoptosis or growth of peripheral tissues through 
various experiments related to apoptosis. Moreover, RNA 
expression was found to be regulated by a variable knock-
down mechanism of RNA interference tools in  vitro and 
in  vivo [60]. The in  vivo analysis easily used adenovirus-
mediated shRNA for effective knockdown of target genes 
and directly-injected tumor tissues. The in vitro analysis also 
used lentiviral-mediated siRNA for effective knockdown of 
target genes in a rapid-growth cell-based assay [60, 61].
Fig. 2 Regulation of hypoxic apoptosis in hepatocellular carcinoma. Apoptosis is an important mechanism for the development of organisms. 
Organisms survive and proliferate in the cyclic structure of cell creation and death. However, apoptosis is critical for inhibiting the growth of cancer 
cells. One of the significant survival mechanisms of cancer cells is the suppression or prevention of apoptosis. Adenovirus-mediated knockdown of 
HIF-1α and IL-8 induced apoptosis in HCC and triggered apoptosis of vascular endothelial cells
Page 7 of 8Choi and Park  Cancer Cell Int  (2017) 17:3 
Various treatments have been developed for cancer, 
and better therapies have been developed by overcom-
ing the limitations of already developed treatments. 
We hypothesized that if the symptoms that occur dur-
ing tumor treatment can be studied and controlled, the 
obstacles currently encountered during cancer treatment 
can be eliminated. If simultaneous regulation of tumor 
development, hypoxia, and angiogenesis is possible, 
cancer cells could be easily treated without peripheral 
damage. In other words, simultaneous inhibition of the 
factors that potentially control hypoxia and angiogen-
esis during treatment to induce apoptosis may be a more 
innovative anticancer treatment modality.
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